Literature DB >> 15876454

CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.

Jana Moravcová, Jana Rulcová, Jaroslav Polák, Zuzana Zemanová, Hana Klamová, Cedrik Haskovec.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15876454     DOI： 10.1016/j.leukres.2005.04.001

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  3 in total

1.  Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.

Authors:  Sarah L McCarron; Stephen E Langabeer; Karen Bolger; Karl Haslam; Mireille Crampe; Johanna Kelly; Ruth Morrell
Journal:  Med Oncol       Date:  2015-01-13       Impact factor: 3.064

2.  Chronic Myeloid Leukemia With Rare Variant b2a3 (e13a3) BCR-ABL1 Fusion.

Authors:  Jihye Ha; June Won Cheong; Saeam Shin; Seung Tae Lee; Jong Rak Choi
Journal:  Ann Lab Med       Date:  2016-05       Impact factor: 3.464

3.  Chronic myeloid leukemia with a rare fusion transcript, b2a3 (e13a3) BCR-ABL1: A report of four cases from India.

Authors:  Sudha Sazawal; Sunita Chhikara; Kanwaljeet Singh; Rekha Chaubey; Manoranjan Mahapatra; Tulika Seth; Renu Saxena
Journal:  South Asian J Cancer       Date:  2019 Apr-Jun
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.